Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute kidney injury
Biotech
Genentech shreds RIPK1 inhibitor after ph. 2 failure
An interim analysis revealed flizasertib was unlikely to prevent heart surgery-induced kidney complications in a phase 2 trial.
Darren Incorvaia
Mar 19, 2026 2:48pm
CalciMedica stock craters as trial stopped over 'safety concern'
Jan 28, 2026 8:40am
Kidney monitor maker Potrero Medical files for bankruptcy
Dec 1, 2023 4:40pm
AM-Pharma cuts staff, CEO leaves as lead asset redirected
Sep 26, 2023 10:39am
Guard argues new data render primary endpoint miss 'irrelevant'
Sep 19, 2023 9:35am
Alloksys fails to stop kidney injury in heart surgery patients
Aug 24, 2023 6:30am
